Sanofi picks up Kad­mon and its trans­plant drug in $1.9B buy­out, giv­ing Sam Wak­sal 2 Big Phar­ma buy­outs un­der his belt

It’s not just hot spaces that Paul Hud­son wants Sanofi to lead in.

The CEO’s lat­est, $1.9 bil­lion M&A gam­ble points straight to Kad­mon $KDMN and its new­ly ap­proved drug, Rezurock, which is billed as a first-in-class treat­ment for chron­ic graft-ver­sus-host dis­ease — and a strong ad­di­tion to Sanofi’s trans­plant port­fo­lio.

For Kad­mon, the buy­out marks a sweet re­ward at the end of an up­hill jour­ney that spanned more than a decade and vin­di­ca­tion for a no­to­ri­ous name in biotech, even if the ul­ti­mate price is ac­tu­al­ly low­er than its IPO price five years ago.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER